StockNews.AI
XTNT
StockNews.AI
166 days

Xtant Medical Reports Fourth Quarter and Full Year 2024 Financial Results

1. XTNT anticipates 28% revenue growth for 2025 without additional capital. 2. Fourth quarter revenue rose 12%, marking gradual financial recovery.

3m saved
Insight
Article

FAQ

Why Bullish?

XTNT's substantial revenue growth reflects positive business momentum. Historically, robust predictions boost investor confidence, potentially driving up stock prices.

How important is it?

The article outlines critical financial growth indicators directly linked to XTNT's operations, impacting investor sentiment and future stock performance.

Why Long Term?

Sustained revenue guidance and ongoing cost management can foster long-term growth. Previous cases show that companies with consistent revenue expectations often see prolonged stock appreciation.

Related Companies

SURGAAPLMDT
Full Year 2024 Revenue Growth of 28% Expects 2025 Revenue of $126 Million to $130 Million Without Need for Additional Capital BELGRADE, MT / ACCESS Newswire / March 6, 2025 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the fourth quarter and year ended December 31, 2024 and provided full year revenue guidance for 2025. Fourth Quarter 2024 Financial Highlights Revenue of $31.5 million, up 12%, compared to the prior year quarter Gross margin of 50.8% compared to 61.0% for the prior year quarter Net loss of $3.2 million compared to a net loss of $4.3 million in the prior year quarter Adjusted EBITDA of $438,000 compared to Adjusted EBITDA loss of $695,000 in the prior year quarter Full Year 2024 Financial Highlights Revenue of $117.3 million, up 28%, compared to the prior year Gross margin of 58.2% compared to 60.8% for the prior year Net loss of $16.4 million compared to net income of $660,000 in the prior year, which included a $11.7 million bargain purchase gain related to the acquisition of Surgalign Holdings Adjusted EBITDA loss of $2.3 million compared to an Adjusted EBITDA loss of $1.4 million in the prior year Recent Business Highlights Subsequent to year end, in the first quarter of 2025, entered into a two-year manufacture and license agreement with automatic renewals with a distributor granting the right to manufacture and supply Xtant's SimpliGraft® product that provides for an upfront payment of $1.5 million and minimum purchase obligations Reduced operating expenses by more than $5 million on an annualized basis since third quarter of 2024.

Related News